CNR1 and Huntington disease: Pharmacologically, strategies targeting CB1/TRPV1 have shown promising therapeutic results in models of pain, spasticity, arthritis, and dyskinesia (Di Marzo et al., 2001, 2002; Brooks et al., 2002; Morgese et al., 2007; Lowin and Straub, 2015) For instance, arvanil, a CB1 agonist, TRPV1 activator, and potent inhibitor of anandamide (AEA) accumulation, alleviates hyperkinesia typical of Huntington’s disease (De Lago et al., 2005).